PuSH - Publikationsserver des Helmholtz Zentrums München

Mishima, E. ; Ito, J.* ; Wu, Z.* ; Nakamura, T. ; Wahida, A. ; Doll, S. ; Tonnus, W.* ; Nepachalovich, P.* ; Eggenhofer, E.* ; Aldrovandi, M. ; Henkelmann, B. ; Yamada, K.i.* ; Wanninger, J. ; Zilka, O.* ; Sato, E.* ; Feederle, R. ; Hass, D, ; Maida, A. ; Mourao, A. ; Linkermann, A.* ; Geissler, E.K.* ; Nakagawa, K.* ; Abe, T.* ; Fedorova, M.* ; Proneth, B. ; Pratt, D.A.* ; Conrad, M.

A non-canonical vitamin K cycle is a potent ferroptosis suppressor.

Nature 608, 778-783 (2022)
Verlagsversion Forschungsdaten DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Ferroptosis, a non-apoptotic form of cell death marked by iron-dependent lipid peroxidation1, has a key role in organ injury, degenerative disease and vulnerability of therapy-resistant cancers2. Although substantial progress has been made in understanding the molecular processes relevant to ferroptosis, additional cell-extrinsic and cell-intrinsic processes that determine cell sensitivity toward ferroptosis remain unknown. Here we show that the fully reduced forms of vitamin K—a group of naphthoquinones that includes menaquinone and phylloquinone3—confer a strong anti-ferroptotic function, in addition to the conventional function linked to blood clotting by acting as a cofactor for γ-glutamyl carboxylase. Ferroptosis suppressor protein 1 (FSP1), a NAD(P)H-ubiquinone reductase and the second mainstay of ferroptosis control after glutathione peroxidase-44,5, was found to efficiently reduce vitamin K to its hydroquinone, a potent radical-trapping antioxidant and inhibitor of (phospho)lipid peroxidation. The FSP1-mediated reduction of vitamin K was also responsible for the antidotal effect of vitamin K against warfarin poisoning. It follows that FSP1 is the enzyme mediating warfarin-resistant vitamin K reduction in the canonical vitamin K cycle6. The FSP1-dependent non-canonical vitamin K cycle can act to protect cells against detrimental lipid peroxidation and ferroptosis.
Impact Factor
Scopus SNIP
Scopus
Cited By
Altmetric
69.504
11.342
26
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Sprache englisch
Veröffentlichungsjahr 2022
HGF-Berichtsjahr 2022
ISSN (print) / ISBN 0028-0836
e-ISSN 1476-4687
Zeitschrift Nature
Quellenangaben Band: 608, Heft: 7924, Seiten: 778-783 Artikelnummer: , Supplement: ,
Verlag Nature Publishing Group
Verlagsort London
Begutachtungsstatus Peer reviewed
POF Topic(s) 30203 - Molecular Targets and Therapies
30201 - Metabolic Health
90000 - German Center for Diabetes Research
Forschungsfeld(er) Genetics and Epidemiology

Helmholtz Diabetes Center
Enabling and Novel Technologies
PSP-Element(e) G-506900-001
A-631900-001
G-501900-251
G-503000-001
Förderungen European Research Council
Scopus ID 85135300913
PubMed ID 35922516
Erfassungsdatum 2022-08-31